Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 213

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Receptor-Targeted Nanoparticles for In vivo Imaging of Breast Cancer

Open access
Yang, Lily, Peng, Xiang-Hong, Wang, Y. Andrew, Wang, Xiaoxia, Cao, Zehong, Ni, Chunchun, Karna, Prasanthi, Zhang, Xinjian, Wood, William C., Gao, Xiaohu, Nie, Shuming, Mao, Hui·2009·Clinical Cancer Research

Abstract

Purpose: Cell-surface receptor-targeted magnetic iron oxide nanoparticles provide molecular magnetic resonance imaging contrast agents for improving specificity of the detection of human cancer. Experimental Design: The present study reports the development of a novel targeted iron oxide nanoparticle using a recombinant peptide containing the amino-terminal fragment of urokinase-type plasminogen activator (uPA) conjugated to magnetic iron oxide nanoparticles amino-terminal fragment conjugated-iron oxide (ATF-IO). This nanoparticle targets uPA receptor, which is overexpressed in breast cancer tissues. Results: ATF-IO nanoparticles are able to specifically bind to and be internalized by uPA receptor–expressing tumor cells. Systemic delivery of ATF-IO nanoparticles into mice bearing s.c. and i.p. mammary tumors leads to the accumulation of the particles in tumors, generating a strong magnetic resonance imaging contrast detectable by a clinical magnetic resonance imaging scanner at a field strength of 3 tesla. Target specificity of ATF-IO nanoparticles showed by in vivo magnetic resonance imaging is further confirmed by near-IR fluorescence imaging of the mammary tumors using near-IR dye-labeled amino-terminal fragment peptides conjugated to iron oxide nanoparticles. Furthermore, mice administered ATF-IO nanoparticles exhibit lower uptake of the particles in the liver and spleen compared with those receiving nontargeted iron oxide nanoparticles. Conclusions: Our results suggest that uPA receptor–targeted ATF-IO nanoparticles have potential as molecularly targeted, dual modality imaging agents for in vivo imaging of breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-08-3289

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 213

Metadata

Authors
Yang, L., Peng, X.-H., Wang, Y. A., Wang, X., Cao, Z., Ni, C., Karna, P., Zhang, X., Wood, W. C., Gao, X., Nie, S., & Mao, H.
Venue
Clinical Cancer Research
Published
2009-07-15
Volume
15
Issue
14
Pages
4722-4732
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2113364712
Cited by
213
References
3
FWCI
14.36
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Receptor-Targeted Nanoparticles for In vivo Imaging of Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-08-3289
The paper
Yang, L., Peng, X.-H., Wang, Y. A., Wang, X., Cao, Z., Ni, C., Karna, P., Zhang, X., Wood, W. C., Gao, X., Nie, S., & Mao, H. (2009). Receptor-Targeted Nanoparticles for In vivo Imaging of Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-08-3289

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.